122 related articles for article (PubMed ID: 29296374)
41. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
[TBL] [Abstract][Full Text] [Related]
42.
Hendriks AM; Brouwers AH; Giannopoulos P; Lefrandt JD; Timens W; Groen HJM; de Bock GH; Jalving M
J Cancer; 2021; 12(2):562-570. PubMed ID: 33391452
[No Abstract] [Full Text] [Related]
43. What
Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
[TBL] [Abstract][Full Text] [Related]
44. [Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment].
Schmücking M; Baum RP; Bonnet R; Junker K; Müller KM
Pathologe; 2005 May; 26(3):178-89. PubMed ID: 15800765
[TBL] [Abstract][Full Text] [Related]
45. Prognostic Value of Dual-Time-Point [
Lee SM; Lee JW; Lee JH; Jo IY; Jang SJ
J Pers Med; 2022 Apr; 12(4):. PubMed ID: 35455708
[TBL] [Abstract][Full Text] [Related]
46. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
[TBL] [Abstract][Full Text] [Related]
47. 3'-Deoxy-3'-(18F) Fluorothymidine Positron Emission Tomography/Computed Tomography in Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Pilot Study.
Lewis S; Chan M; Weiss J; Raziee H; Driscoll B; Bezjak A; Sun A; Lok B; Vines D; Cho J; Bissonnette JP; Raman S; Hope A; Giuliani M
Adv Radiat Oncol; 2022; 7(6):101037. PubMed ID: 36420186
[TBL] [Abstract][Full Text] [Related]
48. Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot Experience.
Genestreti G; Burgio MA; Matteucci F; Piciucchi S; Scarpi E; Monti M; Bucchi L; Parisi E; Crociani L; Gurioli C; Poletti V; Gavelli G
Technol Cancer Res Treat; 2015 Dec; 14(6):721-7. PubMed ID: 24945370
[TBL] [Abstract][Full Text] [Related]
49. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
50. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
[TBL] [Abstract][Full Text] [Related]
51. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
52. The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada.
Beers CA; Pond GR; Wright JR; Tsakiridis T; Okawara GS; Swaminath A
Front Oncol; 2023; 13():1210945. PubMed ID: 37681028
[TBL] [Abstract][Full Text] [Related]
53. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
54. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
55. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study.
Guillem JG; Ruby JA; Leibold T; Akhurst TJ; Yeung HW; Gollub MJ; Ginsberg MS; Shia J; Suriawinata AA; Riedel ER; Mazumdar M; Saltz LB; Minsky BD; Nash GM; Paty PB; Temple LK; Weiser MR; Larson SM
Ann Surg; 2013 Aug; 258(2):289-95. PubMed ID: 23187748
[TBL] [Abstract][Full Text] [Related]
56. Multicentric development and evaluation of [
Lucia F; Louis T; Cousin F; Bourbonne V; Visvikis D; Mievis C; Jansen N; Duysinx B; Le Pennec R; Nebbache M; Rehn M; Hamya M; Geier M; Salaun PY; Schick U; Hatt M; Coucke P; Hustinx R; Lovinfosse P
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1097-1108. PubMed ID: 37987783
[TBL] [Abstract][Full Text] [Related]
57. The efficiency of
Uemura M; Ikeda M; Handa R; Danno K; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Doki Y; Eguchi H
BMC Cancer; 2021 Oct; 21(1):1132. PubMed ID: 34674666
[TBL] [Abstract][Full Text] [Related]
58. PET/CT Imaging of NSCLC with a α
Flechsig P; Lindner T; Loktev A; Roesch S; Mier W; Sauter M; Meister M; Herold-Mende C; Haberkorn U; Altmann A
Mol Imaging Biol; 2019 Oct; 21(5):973-983. PubMed ID: 30671741
[TBL] [Abstract][Full Text] [Related]
59. Associations between detectable circulating tumor DNA and tumor glucose uptake measured by
Ottestad AL; Johansen H; Halvorsen TO; Dai HY; Wahl SGF; Emdal EF; Grønberg BH
BMC Cancer; 2023 Jul; 23(1):646. PubMed ID: 37434111
[TBL] [Abstract][Full Text] [Related]
60. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]